Evidence map›Paper›PMID 37522210›Full record

ArticleJournal of Alzheimer's disease : JAD2023

Neuropathologic Changes of Alzheimer's Disease and Related Dementias: Relevance to Future Prevention.

Lon R White, Maria M Corrada, Claudia H Kawas, Brenna A Cholerton, Steve E Edland, Margaret E Flanagan, Thomas J Montine

Open access · greenAbstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Neuropsychiatric symptom subtypes and dementia-associated neuropathologic change.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  5. Review
  6. The Nun Study: Insights from 30 years of aging and dementia research.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Paradigm Shift: Multiple Potential Pathways to Neurodegenerative Dementia.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Lon R WhitePacific Health Research and Education Institute, Honolulu, HI, USA.
Maria M CorradaDepartment of Neurology, UC Irvine, Irvine, CA, USA.
Claudia H KawasDepartment of Neurology, UC Irvine, Irvine, CA, USA.
Brenna A CholertonDepartment of Pathology, Stanford University, Palo Alto, CA, USA.
Steve E EdlandSchool of Public Health and Human Longevity Science, University of California at San Diego, School of Public Health, La Jolla, CA, USA.
Margaret E FlanaganUniversity of Texas Health San Antonio, Biggs Institute for Alzheimer's and Neurodegenerative Diseases and Department of Pathology, San Antonio, TX, USA.
Thomas J MontineDepartment of Pathology, Stanford University, Palo Alto, CA, USA.
University of California, Irvine · USHuman Longevity (United States) · USInstitute for Neurodegenerative Disorders · USPacific Health Research and Education Institute · USPalo Alto University · USStanford University · US

Funding

UC Irvine Alzheimer's Disease Research Center Induced Pluripotent Stem Cell CoreP50AG016573 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI LAFERLA, FRANK M · 2000 to 2019
$37.0M
Diversity Supplement to R01AG021055; Clinical, Imaging, and Pathological Studies in the Oldest Old: The 90+ StudyR01AG021055 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI CORRADA, MARIA, KAWAS, CLAUDIA H. · 2002 to 2024
$36.9M
Neuropathologic substrates for motor and cognitive impairment in three existing cohort studies of Alzheimer's disease and related dementiasUF1AG057707 · NIA · STANFORD UNIVERSITY · PI MONTINE, THOMAS J, WHITE, LON RAY · 2017 to 2017
$3.9M
Cognitive resilience to Alzheimer neuropathologic changes in the Honolulu-Asia Aging Study and the Nun StudyUF1AG053983 · NIA · PACIFIC HEALTH RESEARCH/ EDUCATION INST · PI MONTINE, THOMAS J, WHITE, LON RAY · 2016 to 2016
$2.6M
NIA NIH HHS P50 AG016573NIA NIH HHS R01 AG021055NIA NIH HHS UF1 AG053983NIA NIH HHS UF1 AG057707
6 · The paper itself

Abstract

backgroundDecedents with late-life dementia are often found at autopsy to have vascular pathology, cortical Lewy bodies, hippocampal sclerosis, and/or TDP-43 encephalopathy alone or with concurrent Alzheimer's disease (AD) lesions. Nonetheless, it is commonly believed that AD neuropathologic changes (NC) are the dominant or exclusive drivers of late-life dementia.

objectiveAssess associations of end-of-life cognitive impairment with any one or any combination of five distinct NC. Assess impairment prevalence among subjects having natural resistance to each type of NC.

methodsBrains from 1,040 autopsied participants of the Honolulu-Asia Study, the Nun Study, and the 90 + Study were examined for NC of AD, Lewy body dementia, microvascular brain injury, hippocampal sclerosis, and limbic predominate TDP-43 encephalopathy. Associations with impairment were assessed for each NC and for NC polymorbidity (variable combinations of 2-5 concurrent NC).

resultsAmong 387 autopsied decedents with severe cognitive impairment, 20.4% had only AD lesions (ADNC), 25.3% had ADNC plus 1 other NC, 11.1% had ADNC plus 2 or more other NC, 28.7% had no ADNC but 1-4 other NC, and 14.5% had no/negligible NC. Combinations of any two, three, or four NC were highly frequent among the impaired. Natural resistance to ADNC or any other single NC had a modest impact on overall cohort impairment levels.

conclusionPolymorbidity involving 1-5 types of concurrent NC is a dominant neuropathologic feature of AD and related dementias. This represents a daunting challenge to future prevention and could explain failures of prior preventive intervention trials and of efforts to identify risk factors.

Indexed as

Alzheimer DiseaseCognitive DysfunctionLewy Body DiseaseBrainDNA-Binding ProteinsHumansDNA-Binding ProteinsAlzheimer’s diseaseAlzheimer’s disease and related dementiasautopsyco-morbiditydementianeuropathologypolymorbidityprevention

Identifiers

PMID37522210
PMCPMC10851925
OpenAlexW4385249317

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.